GENEVA--(BUSINESS WIRE)--In line with this year’s theme for the annual European Society for Medical Oncology (ESMO) Congress - ‘Precision Medicine in Cancer Care’ - Genomic Health presented results from multiple studies across different cancer types demonstrating how its genomic test Oncotype DX has led to a greater understanding of cancer at the molecular level, enabling more personalised treatment decisions.
Data from the additional prostate cancer clinical validation study1 confirm that the Genomic Prostate Score (GPS) provided by the Oncotype DX prostate cancer test is a significant predictor of disease aggressiveness at the time of diagnosis based on assessment of biopsies from the tumour and provides information beyond currently available risk factors. In particular, this new study confirms Oncotype DX as a predictor of adverse pathology from the biopsy, as previously demonstrated in a published validation study2, and demonstrates the test’s ability to predict the risk of recurrence after surgery.
Help employers find you! Check out all the jobs and post your resume.
Data from the additional prostate cancer clinical validation study1 confirm that the Genomic Prostate Score (GPS) provided by the Oncotype DX prostate cancer test is a significant predictor of disease aggressiveness at the time of diagnosis based on assessment of biopsies from the tumour and provides information beyond currently available risk factors. In particular, this new study confirms Oncotype DX as a predictor of adverse pathology from the biopsy, as previously demonstrated in a published validation study2, and demonstrates the test’s ability to predict the risk of recurrence after surgery.
Help employers find you! Check out all the jobs and post your resume.
